These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28393573)

  • 1. Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.
    Sambamoorthi U; Garg R; Deb A; Fan T; Boss A
    Curr Med Res Opin; 2017 Jul; 33(7):1309-1316. PubMed ID: 28393573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens.
    Sambamoorthi U; Deb A; Zhou S; Garg R; Fan T; Boss A
    J Diabetes Res; 2016; 2016():5374931. PubMed ID: 27761472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
    Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
    Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
    Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
    Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.
    Dalal MR; Xie L; Baser O; DiGenio A
    Endocr Pract; 2015 Jan; 21(1):68-76. PubMed ID: 25148821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.
    Wysham CH; Lin J; Kuritzky L
    Postgrad Med; 2017 May; 129(4):436-445. PubMed ID: 28294702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
    Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel option for prandial insulin therapy: inhaled insulin.
    Dailey G; Ahmad A; Polsky S; Shah V
    Postgrad Med; 2016 Nov; 128(8):839-847. PubMed ID: 27580306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
    Buysman EK; Liu F; Hammer M; Langer J
    Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
    Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
    JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin.
    Zhou FL; Xie L; Pan C; Wang Y; Vaidya N; Ye F; Preblick R; Meneghini L
    Diabetes Obes Metab; 2018 May; 20(5):1298-1301. PubMed ID: 29278460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targets.
    Migdal A; Abrahamson M; Peters A; Vint N
    Ann Med; 2018 Sep; 50(6):453-460. PubMed ID: 30103624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
    Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
    Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effort required to achieve and maintain optimal glycemic control.
    Rosenthal ES; Bashan E; Herman WH; Hodish I
    J Diabetes Complications; 2011; 25(5):283-8. PubMed ID: 21367626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.